# Menopause-Related Vasomotor Symptoms Market

> Menopause-Related Vasomotor Symptoms Market Research Report: Information by Treatment Type (Hormone Therapy, Non-Hormonal Treatment and Dietary Supplements), By Menopause Stage (Premature Menopause, Perimenopause and Post-menopause), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, and Online Channels) By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa) -Global Forecast to 2035.

- **Forecast Period:** 2025 - 2035
- **CAGR:** 5.1%
- **2024:** $ 12,819.89 Million
- **2025:** $ 13,221.15 Million
- **2035:** $ 21,548.35 Million
- **Key Players:** Companies such as Pfizer Inc., Bayer AG, Astellas Pharma Inc., Cipla, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Zydus Group, Hikma Pharmaceuticals Plc. are some of the major participants in the global market.

**Report ID:** MRFR/Pharma/66574-CR · **Pages:** 100 · **Author:** Snehal Singh & Rahul Gotadki · **Last Updated:** May 21, 2026

**URL:** https://www.marketresearchfuture.com/reports/menopause-related-vasomotor-symptoms-market-68374

---

## Market Drivers

### Strong Clinical Effectiveness of Hormone Therapy

Hormone therapy (HT), primarily involving estrogen and progesterone, remains a cornerstone in managing menopause-related vasomotor symptoms (VMS) such as hot flashes and night sweats. Its clinical effectiveness is well-established, with numerous studies demonstrating significant symptom relief.
 
For instance, the Women's Health Initiative (WHI) trial, although initially highlighting some risks, also confirmed that estrogen therapy effectively reduces VMS severity and frequency in menopausal women. A meta-analysis published in the Cochrane Database of Systematic Reviews (2019) further supports this, indicating that estrogen therapy can alleviate hot flashes in approximately 75-80% of women, often within weeks of initiation.

### Approval & Launch of Novel Non-Hormonal Neurokinin Receptor Antagonists

The approval and subsequent launch of novel non-hormonal neurokinin-3 (NK3) receptor antagonists have significantly advanced the management of menopause-related vasomotor symptoms (VMS), such as hot flashes and night sweats.
 
Traditionally, hormone replacement therapy (HRT) has been the primary treatment, but concerns regarding its associated risks including increased chances of breast cancer, cardiovascular events, and thromboembolism have driven the search for safer alternatives.
 
On May 12, 2023, the U.S. Food and Drug Administration (FDA) approved fezolinetant (brand name Veozah), marking a historic milestone as the first-in-class non-hormonal treatment for moderate to severe VMS.

## Future Outlook

The Menopause-Related Vasomotor Symptoms Market size is projected to reach USD 21,548.35 Million by 2035, growing at a CAGR of 5.1%, driven by increasing demand for high-performance computing and enhanced security features.

**New opportunities:**

- Development and Expansion of Novel Neurokinin (NK3) Receptor Antagonists. Female-Focused & Customized Solutions.

## Segment Insights

### By Treatment Type: Hormone Therapy (largest market) vs Non-Hormonal Treatment (fastest growing)

Based on Treatment, the Menopause-Related Vasomotor Symptoms Industry has been segmented into Hormone Therapy, Non-Hormonal Treatment and Dietary Supplements. The hormone therapy segment held the largest market share of 68% in 2025, while the non-hormonal therapy segment is the fastest-growing segment during the forecast period. Hormone Therapy is bifurcated into Estrogen-only Therapy, and Non-Hormonal Treatment. Non-Hormonal Treatment is bifurcated into Neurokinin, SSRIs/SNRIs, Gabapentinoids and Others.

### By Menopause Stage: Post-menopause (largest market) vs Perimenopause (fastest-growing)

Based on Menopause Stage, the Menopause-Related Vasomotor Symptoms Market has been segmented into Premature Menopause, Perimenopause and Post-menopause. The post-menopause segment held the largest market share of 62% in 2025, while the perimenopause segment is the fastest-growing segment during the forecast period.

### By Distribution Channel: Hospital Pharmacy (largest market) vs Retail Pharmacy (fastest-Growing)

Based on Distribution Channel, the Menopause-Related Vasomotor Symptoms Market has been segmented into Hospital Pharmacy, Retail Pharmacy, and Online Channels. The Hospital Pharmacies segment held the largest market share at 55% in 2025, while the Online Channels segment is the fastest-growing segment during the forecast period.

## Regional Market Share Analysis

### North America**:**Expanding strong awareness of menopause

North America is the largest and most mature VMS treatment market, with the United States alone accounting for the highest share of global vasomotor‑symptoms revenues. Growth is driven by a large aging female population, strong awareness of menopause as a medical condition, and relatively robust reimbursement for both hormonal and non‑hormonal therapies.

The region is an innovation hub for next‑generation treatments, including FDA‑approved non‑hormonal neurokinin‑3 receptor antagonists such as Veozah, which are reshaping VMS care pathways. Digital health, telemedicine, and direct‑to‑consumer platforms are widely adopted, enabling remote consultations, symptom tracking, and personalized treatment plans that strengthen patient engagement and adherence.

- CDC reports that women constitute nearly 51% of the U.S. population, with millions entering menopause annually, creating sustained demand for treatment solutions. WHO highlights that high-income regions show greater access to hormone and non-hormone therapies, while digital health adoption enhances treatment adherence and early intervention for chronic menopausal symptoms.

### Europe: Strong Production widespread clinical‑guideline adoption

Europe holds a significant share of the VMS market, supported by well‑established healthcare systems, widespread clinical‑guideline adoption, and active research in hormone and non‑hormonal therapies. Countries in Western and Northern Europe exhibit high diagnosis and treatment rates for moderate‑to‑severe vasomotor symptoms, while Central and Eastern Europe are catching up as awareness and access improve.

The market is characterized by a balanced mix of branded hormone replacement therapies, generics, and emerging non‑hormonal agents, with strong emphasis on long‑term safety and cardiovascular‑risk mitigation. Regulatory scrutiny has pushed manufacturers toward lower‑dose, tissue‑selective, and short‑term regimens, while women’s‑health advocacy and media campaigns are reducing stigma and encouraging earlier treatment seeking.

- UN DESA indicates that Europe is the most aged region globally, with over 20% of its population already aged 65 or older in many countries. WHO Europe emphasizes structured healthcare systems that support chronic condition management, improving access to menopause-related therapies and strengthening long-term women’s health outcomes across the region.

### Asia Pacific: Rising life expectancy, urbanization

Asia‑Pacific is the fastest‑growing region for VMS‑related care, with China, India, Japan, and Southeast Asian economies driving expansion. Rising life expectancy, urbanization, and a growing middle‑class female population are increasing the number of women in the 45–65 age band, expanding the addressable market. Awareness of menopause as a treatable condition is growing, especially in urban centers, leading to higher uptake of both hormonal therapies and herbal or nutraceutical supplements such as phytoestrogen‑rich products. However, market growth is tempered by uneven healthcare infrastructure, limited menopause‑specialized providers in rural areas, cost constraints, and persistent cultural taboos around discussing reproductive‑age transitions.

### South America: Protection of increasingly offering generic hormone

South America exhibits moderate growth, with Brazil, Mexico, and Colombia leading demand. The region benefits from a sizable female population entering menopause and improving access to gynecological and women’s‑health services, yet treatment penetration remains below North American and European levels.

Patients show strong interest in non‑hormonal and natural remedies, and local manufacturers are increasingly offering generic hormone therapies and herbal supplements tailored to regional preferences. Challenges include variable insurance coverage, price sensitivity, and uneven distribution of specialist care, but telehealth and regional marketing campaigns are helping to broaden access and awareness.

### Middle East & Africa: Expansion of specialty‑care networks

Middle East & Africa (MEA) shows structurally positive but slower growth, anchored by government‑led women’s‑health initiatives, NGO‑supported awareness‑raising, and gradual expansion of specialty‑care networks. In Gulf Cooperation Council (GCC) countries, higher healthcare spending and private‑sector‑driven clinics are fostering early adoption of modern VMS therapies, including hormone and non‑hormonal options.

In Sub‑Saharan African markets, growth is constrained by limited awareness, fragmented primary‑care systems, and affordability barriers, although rising education levels and digital‑media penetration are beginning to normalize discussions around menopause and symptom management.

## Competitive Benchmarking

Many global, regional, and local vendors characterize the Menopause-Related Vasomotor Symptoms Market. The global market is highly competitive, with all the players competing to gain market share. Intense competition, rapid advances in Treatment, frequent changes in government policies, and environmental regulations are key factors that confront market growth. The vendors compete based on cost, product quality, reliability, and government regulations. 
Vendors must provide cost-efficient, high-quality products to survive and succeed in an intensely competitive market.
The major players in the global industry Include Pfizer Inc., Bayer AG, Astellas Pharma Inc., Cipla, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Zydus Group, Hikma Pharmaceuticals Plc, strategic market developments and decisions to improve operational effectiveness.

## Recent News & Developments

August 2025: Approved by the U.S. FDA for treatment of moderate to severe vasomotor symptoms (VMS) due to menopause. Elinzanetant is the first dual neurokinin receptor antagonist (NK1 and NK3), acting on KNDy neurons to regulate thermoregulation associated with hot flashes. Approval is supported by Phase III OASIS 1, 2, and 3 trials, demonstrating significant reduction in frequency and severity of hot flashes at weeks 4 and 12.

Safety evaluated in 1,420 women, including long-term data up to 52 weeks. Represents a first-in-class, hormone-free treatment option addressing unmet need in menopause care, with availability in the U.S. starting November 2025 and approvals across multiple global markets.

April 2025: Approved by Health Canada as the first non-hormonal treatment for moderate to severe vasomotor symptoms (VMS) associated with menopause. The launch is supported by the BRIGHT SKY Phase 3 program (SKYLIGHT 1, 2, and 4 trials) involving over 2,850 patients across the US, Canada, and Europe, demonstrating efficacy in reducing hot flashes and night sweats and establishing long-term safety. The therapy works via neurokinin B receptor antagonism in the hypothalamus. It has also received approvals in the US, UK, Australia, and Europe, with ongoing Phase 3 evaluation (HIGHLIGHT 1) in breast cancer patients.

March 2025: Pfizer Inc. announced that DUAVEE, an estrogen-based menopause hormone therapy used to treat moderate-to-severe hot flashes and help prevent postmenopausal osteoporosis, has returned to the U.S. market after a voluntary recall issued in May 2020 due to packaging stability issues. Following packaging improvements and regulatory updates, the product is now back in stock with enhanced packaging to ensure shelf-life stability, and Pfizer plans to make it available in additional markets after completing local regulatory reviews. 

## Report Scope

| Market Size 2024 |  12,819.89 (USD Million) |
| --- | --- |
| Market Size 2025 | 13,221.15 (USD Million) |
| Market Size 2035 | 21,548.35 (USD Million) |
| Compound Annual Growth Rate (CAGR) | 5.1% (2025 - 2035) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Pfizer Inc., Bayer AG, Astellas Pharma Inc., Cipla, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Zydus Group, Hikma Pharmaceuticals Plc |
| Segments Covered | By Treatment Type By Menopause Stage By Distribution Channel |
| Key Market Opportunities | Development and Expansion of Novel Neurokinin (NK3) Receptor Antagonists Female-Focused & Customized Solutions. |
| Key Market Dynamics | Rising Global Menopausal Population & Aging Female Population High Prevalence of Vasomotor Symptoms Approval & Launch of Novel Non-Hormonal Neurokinin Receptor Antagonists Strong Clinical Effectiveness of Hormone Therapy. |
| Region Covered | North America, Europe, Asia Pacific, South America, Middle East & Africa. |

## Frequently Asked Questions

**Q: How much is the Menopause-Related Vasomotor Symptoms Market?**
A: USD 21,548.35 Million (2035) is the Menopause-Related Vasomotor Symptoms Market

**Q: What is the growth rate of the Menopause-Related Vasomotor Symptoms Market?**
A: 5.1% is the growth rate of the Menopause-Related Vasomotor Symptoms Market

**Q: Which region held the largest market share in the Menopause-Related Vasomotor Symptoms Market?**
A: North America held the largest market share in the Menopause-Related Vasomotor Symptoms Market.

**Q: Who are the key players in the Menopause-Related Vasomotor Symptoms Market?**
A: Pfizer Inc., Bayer AG, Astellas Pharma Inc., Cipla, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Zydus Group, Hikma Pharmaceuticals Plc are the key players in the Menopause-Related Vasomotor Symptoms Market.

**Q: Which Distribution Channel had the largest market share in the Menopause-Related Vasomotor Symptoms Market?**
A: Hospital Pharmacy had the largest market share in the Menopause-Related Vasomotor Symptoms Market.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/menopause-related-vasomotor-symptoms-market-68374*